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predicted for clinical and biochemical failures. MVA indicates 
that RBP is an independent risk factor for biochemical failure 
(p=0.003, HR=0.6) while it is the strongest risk factor for 
clinical failures and PCa deaths (p<0.0001, HR<0.5, regression 
coefficient b<-0.5). No statistical significant difference in 
rectal volume between RBP (mean volume 62.4±24.5 cc) and 
NRPB (mean volume 63.4±27 cc) was observed (chi square p 
value equal to 0.52) 
 
 
 
Conclusion: We found strong evidence that rectal/bladder 
preparation significantly decreased (HR<0.6, b<-0.5) the 
probability of death from PCa, biochemical and clinical 
failures in patients who were treated with 3DCRT for PCa 
without daily image-guided prostate localization, presumably 
because pts with RBP are able to maintain a reproducible 
empty rectum and comfortable full bladder for all the 
treatment. These results also emphasize the routinely need 
of image-guided radiotherapy to improve outcome in prostate 
cancer patients 
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Purpose or Objective: The aim of the study is to 
prospectively evaluate urinary symptoms using the 
International Prostate Symptom Score (IPSS) in patients with 
localized prostate cancer (CaP) treated with radical (RRT) or 
postprostatectomy (PRT) radiotherapy delivered with 
conventional (CONV) or moderately hypofractionated (HYPO) 
fractionation. 
 
Material and Methods: We considered patients enrolled in 
the two multicentric prospective observational studies DUE01 
(RRT, CONV and HYPO) and IHU WPRT TOX (RRT and PRT, 
including irradiation of the pelvic lymphnodal area, CONV 
and HYPO). The IPSS questionnaire, evaluating 7 symptoms 
(IPSS1-IPSS7) and a quality of life (IPSS8), is filled in before 
and at the end of RT, then 3 and 6 after treatment end and 
every 6 months thereafter up to 5 years after the end of 
treatment. In this preliminary analysis only data relative to 
first year will be analyzed. Longitudinal trends were assessed 
by analysis of variance (anova). 
 
Results: The analysis pertains to 146 RRT CONV pts, 104 RRT 
HYPO pts, 74 PRT CONV pts and 94 PRT HYPO. The median 
age in the 2 studies was 71 (RRT) and 66 (PRT) years (p = 
0.0001). Overall, urinary function was always better in the 
RRT CONV cohort. Statistically significant differences among 
the 4 groups have emerged with respect to urinary 
frequency, urgency, effort, nocturia. When comparing RRT vs 
PRT, frequency (p = 0.007) and stress (p = 0.01) were 
significantly more present in PRT, while only a borderline 
difference in terms of urgency (p = 0.07) was evident. The 
last item of IPSS shows a significant difference of quality of 
life between groups, especially at 12 month where RRT 
cohort, especially CONV, shows a better score than PRT 
patients. Figure 1 shows the comparison of each group for all 
IPSS items (incomplete emptyng, urinary frequency, 
intermittence, urgency, urinary stream, obstruction, 
nocturia, QoL), evaluating the mean response in the first five 
time of compilation (Rt start, RT end, 3m, 6m, 12m). 
 
 
Conclusion: These preliminary results seem to suggest that 
RRT would result in less deterioration of urinary symptoms 
over time than PRT, especially RRT with conventional 
fractionation. Further analyses are ongoing in order to study 
the effect of baseline urinary situation, age, doses to the 
bladder and the impact of each urinary symptoms on quality 
of life.  
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Purpose or Objective: Although intensity modulated 
radiotherapy (IMRT) permits the delivery of a highly 
conformal dose to target volumes while sparing dose to 
identified organs at risk, it results in a higher whole body 
integral dose due to irradiation of a larger volume of tissue at 
lower doses. A randomized clinical trial in head and neck 
cancer comparing IMRT with 3-D conformal radiotherapy, 
demonstrated higher acute fatigue in the IMRT cohort, raising 
the possibility of an association with higher integral dose. We 
hypothesized that a higher integral whole body dose is 
associated with worsening fatigue and an adverse functional 
outcome in patients with localized prostate cancer treated 
with intensity modulated external beam radiotherapy.  
 
Material and Methods: 26 patients with localized 
adenocarcinoma of prostate treated with intensity modulated 
external beam radiotherapy were included in this analysis. 
The integral dose was calculated as the product of mean 
body dose and body volume and the study cohort was 
dichotomized using the median integral dose as the cut-off 
value. The fatigue, physical functioning and role functioning 
domains of the EORTC QLQ-C30 questionnaire prior to 
radiotherapy and upon completion of radiotherapy were 
assessed. The outcome measure was defined as worsening in 
any of these three domains. 
 
Results: The median integral dose was 119.7 litre-Gy (range 
90.5 – 168.1). In the whole population 17/26 (65%) had 
worsening of fatigue, physical or role functioning. A 
significantly higher proportion of patients with an integral 
dose above median had worsening fatigue, physical and role 
functioning compared with patients with an integral dose 
below median. (6/13 versus 11/13; z test for proportions 
p=0.04). 
 
Conclusion: To our knowledge, this is the first study linking 
acute worsening of fatigue and functional outcome with 
whole body integral dose. Further validation in a larger 
cohort and in different tumour sites is necessary and the 
relationship between integral dose and toxicity merits further 
investigation. 
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Purpose or Objective: To prospectively evaluate acute 
intestinal toxicity (AIT) from RT including whole-pelvis 
irradiation (WPRT) for prostate cancer by means of a 
validated questionnaire (IBDQ, Intestinal Bowel Disease 
Questionnaire), and to investigate the intestinal symptoms 
that most affect patient quality of life (QoL). 
 
Material and Methods: In 2014 a multicentric, observational 
trial aimed at assessing IT from RT including WPRT was 
activated. Prior to study activation, a pilot feasibility study 
was started in the coordinating Institute. For the study’s 
purpose, the IBDQ is to be filled in by pts at baseline, RT 
mid-point and end, 3 and 6 months, and thereafter every 6 
months up to 5 years. The questionnaire comprises 32 items 
investigating bowel symptoms (10 items), emotional health 
(12), systemic symptoms (5) and social function (5). The 
responses are scored on a seven-point scale in which 7 
corresponds to the best function and 1 to the worst. Average 
per item scores can be calculated for each of the 4 domains. 
This analysis pertains to the first 144 pts (8 Institutes) with 
complete data available at baseline, RT mid-point and end. 
Initially, only pts treated with post-prostatectomy RT with 
either adjuvant (ADV, n= 71) or salvage (SALV, n=73) intent 
were enrolled. Pts were treated with static-field IMRT 
(n=31), Tomotherapy (n=42) and VMAT (n=71), with 
conventional (1.8-2 Gy/fr, n=78) or moderate 
hypofractionation (2.15-2.65 Gy/fr, median 2.35, n=66). The 
median EQD2 dose to the prostatic bed and pelvic lymph-
nodal area was 71.2 and 50 Gy, respectively. 58 pts received 
concomitant androgen deprivation. 
 
Results: Overall, self-perceived intestinal toxicity from WPRT 
was mild: mean scores for bowel symptoms at baseline, RT 
mid-point and end were in fact 6.58, 6.09, 5.90 (repeated 
measures Anova, p<0.0001), for emotional health 
5.94,5.79,5.69 (0.0003), for social function 6.20, 5.83, 5.65 
(p<0.0001) and for systemic symptoms 5.95, 5.55, 5.40 
(p<0.0001), respectively. For the evaluation of acute toxicity, 
the worst variation (delta) between baseline and RT mid-
point or end was considered. With respect to the bowel 
symptoms, the median score decrease (worsening) was 2 
points for only one item (frequent bowel movements), 1 
point for loose bowel movements, gas passage, abdominal 
bloating and urge to defecate, and 0 for abdominal pains and 
cramps, rectal bleeding, accidental soiling and nausea. 
Nevertheless, abdominal pain and urge to defecate were the 
two items with higher predictive power (AUC 72-79% at ROC 
curve analysis) with respect to a worsening of ³1 point (25th 
percentile) of either emotional or systemic or social domains, 
as well as gas passage, urge to defecate and nausea (AUC 72-
73%) for emotional. 
 
Conclusion: The self assessed AIT from WPRT delivered by 
means of modern IMRT technique is negligible. Abdominal 
pain and urge to defecate are the 2 symptoms mostly 
correlated with a worsening of patient’s QoL. 
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